Share This Author
Evidence for the Involvement of Dopamine Transporters in Behavioral Stimulant Effects of Modafinil
- D. Żółkowska, R. Jain, M. Baumann
- Biology, ChemistryJournal of Pharmacology and Experimental…
- 1 May 2009
The data show that modafinil interacts with DAT sites in rat brain, a property shared with agonist medications under investigation for treating cocaine dependence, and suggest that modAFinil should be tested as an adjunct for treating METH addiction.
Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum.
Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity.
Dose-related effects of salvinorin A in humans: dissociative, hallucinogenic, and memory effects
- Katherine A. MacLean, Matthew W. Johnson, C. Reissig, T. Prisinzano, R. Griffiths
- Psychology, MedicinePsychopharmacology
- 1 March 2013
Salvinorin A produces a unique profile of subjective and cognitive effects, including strong dissociative effects and memory impairment, which only partially overlap with classic hallucinogen effects.
Pharmacokinetics of the plant‐derived κ‐opioid hallucinogen salvinorin A in nonhuman primates
Pharmacokinetic differences were observed between males and females, suggesting potential sex differences in its pharmacologic effects, and Salvinorin B, the presumed major metabolite, is observed to accumulate ex vivo; however, in this study it never reached the limit of detection.
Salvinorin A regulates dopamine transporter function via a kappa opioid receptor and ERK1/2-dependent mechanism
Evaluation of the transport, in vitro metabolism and pharmacokinetics of Salvinorin A, a potent hallucinogen.
R-Modafinil (Armodafinil): A Unique Dopamine Uptake Inhibitor and Potential Medication for Psychostimulant Abuse
Development of Functionally Selective, Small Molecule Agonists at Kappa Opioid Receptors*
Two first-in-class small molecule agonists that bias KOR signaling toward G protein coupling and away from βarrestin2 recruitment are described, which may prove to be useful tools for refining the therapeutic potential of KOR-directed signaling in vivo.